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Cell type–specific DNA methylation at intragenic
CpG islands in the immune system
Aime´e M. Deaton,1 Shaun Webb,1 Alastair R.W. Kerr,1 Robert S. Illingworth,1
Jacky Guy,1 Robert Andrews,2 and Adrian Bird1,3
1Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3JR, United Kingdom; 2Wellcome Trust Sanger Centre,
Hinxton, Cambridge CB10 1SA, United Kingdom
Human and mouse genomes contain a similar number of CpG islands (CGIs), which are discrete CpG-rich DNA se-
quences associated with transcription start sites. In both species, ~50% of all CGIs are remote from annotated pro-
moters but, nevertheless, often have promoter-like features. To determine the role of CGI methylation in cell
differentiation, we analyzed DNA methylation at a comprehensive CGI set in cells of the mouse hematopoietic lineage.
Using a method that potentially detects ~33% of genomic CpGs in the methylated state, we found that large differences
in gene expression were accompanied by surprisingly few DNAmethylation changes. There were, however, many DNA
methylation differences between hematopoietic cells and a distantly related tissue, brain. Altered DNA methylation in
the immune system occurred predominantly at CGIs within gene bodies, which have the properties of cell type–
restricted promoters, but infrequently at annotated gene promoters or CGI flanking sequences (CGI ‘‘shores’’). Un-
expectedly, elevated intragenic CGI methylation correlated with silencing of the associated gene. Differentially
methylated intragenic CGIs tended to lack H3K4me3 and associate with a transcriptionally repressive environment
regardless of methylation state. Our results indicate that DNA methylation changes play a relatively minor role in the
late stages of differentiation and suggest that intragenic CGIs represent regulatory sites of differential gene expression
during the early stages of lineage specification.
[Supplemental material is available for this article. The sequencing and gene expression data from this study have been
submitted to the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under accession nos. GSE25688 and
GSE25578, respectively.]
The dinucleotide sequence CpG is the predominant site of DNA
methylation in the vertebrate genome, but not all CpGs are
methylated. Two fractions can be discerned based onCpGdensity
and methylation status: The bulk of the genome is CpG-deficient
and predominantly methylated (;80%), while discrete regions
called CpG islands (CGIs) are on average tenfold more CpG-rich,
usually unmethylated, and associated with the histone modifi-
cation H3K4me3 (Guenther et al. 2007; Mikkelsen et al. 2007;
Illingworth and Bird 2009; Thomson et al. 2010). The majority of
gene promoters (;60%) are included within CGIs. CGI methyl-
ation is invariably associated with promoter silencing, although
silenced CGI promoters often remain in a nonmethylated state
(Weber et al. 2007). For example, the alpha globin CGI is unme-
thylated even in nonerythroid tissues (Bird et al. 1987). DNA
methylation-associated gene silencing is well documented during
X chromosome inactivation, imprinting, and cancer (Edwards
and Ferguson-Smith 2007; Jones and Baylin 2007; Payer and Lee
2008), but recent genome-wide studies have described many
additional instances in normal somatic cells. A number of these
described the acquisition of CGI methylation in somatic cell
lineages, compared to the germline, where CGIs are almost in-
variably hypomethylated (Schilling and Rehli 2007; Weber et al.
2007; Illingworth et al. 2008). CGI methylation has also been
analyzed during differentiation of embryonic stem cells (Mohn
et al. 2008). Most DNAmethylation studies have focused on CGIs
occurring at annotated gene promoters (Weber et al. 2007;
Meissner et al. 2008; Mohn et al. 2008), but it has become appar-
ent that CGIs remote from annotated transcription start sites
(TSSs), located either between genes or within the body of a tran-
scription unit, exhibit a high degree of tissue-specific methylation
(Illingworth et al. 2008; Rauch et al. 2009; Maunakea et al. 2010).
These so-called ‘‘orphan CGIs’’ account for about half of all CGIs in
human and mouse genomes (Illingworth et al. 2010). Despite the
absence of annotated promoters within orphan CGIs, many are
marked byH3K4me3 and RNA polymerase II (RNAPII) and give rise
to detectable transcripts (Illingworth et al. 2010; Maunakea et al.
2010). Therefore, CpG methylation at these sites may be involved
in silencing novel uncharacterized promoters. These findings raise
questions about the functional significance of orphan CGI pro-
moters and the dynamics of their methylation during devel-
opment and differentiation.
To address these issues, we have studied cells of the immune
system, which are derived from a common progenitor, the hema-
topoietic stem cell (Fig. 1A), and therefore offer a convenient
system in which to investigate the role of DNA methylation in
differentiation. Pure primary cells from the immune lineage can be
isolated using fluorescence activated cell sorting (FACS) or mag-
netic bead purification, avoiding the need to analyze DNA meth-
ylation patterns in mixed lineage tissues or in cultured cell lines
whereDNAmethylation is known to be abnormal (Antequera et al.
1990; Jones et al. 1990; Smiraglia et al. 2001; Meissner et al. 2008).
Changes in DNA methylation at specific genes have already been
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documented in this system, most notably during T helper cell
differentiation. Upon infection, CD4+ T helper cells are activated
and then specialize further in response to different kinds of in-
fection (Reiner 2007;Wan 2010). Th1 cells coordinate the immune
response to intracellular bacteria and viruses, while Th2 cells re-
spond to infectionby extracellular parasites. The key cytokine gene
loci, Ifng in Th1 cells and Il4 in Th2 cells, undergo changes in DNA
methylation during T helper cell differentiation (Lee et al. 2002;
Santangelo et al. 2002; Winders et al. 2004; Schoenborn et al.
2007), a process that can be recapitulated in vitro.
In this study, we have coupled the biochemical isolation of
methylated CpG-rich DNA with high-throughput sequencing
methods (MAP-seq) (Illingworth et al. 2010) to allow compre-
hensive, unbiased profiling of DNA methylation in immune
cells. We identified cell type–specific CGImethylation occurring
during T helper cell differentiation and compared methylation
patterns between T helper cell subtypes and more distantly re-
lated B cells and dendritic cells (Fig. 1A). The number of changes
in gene expression between these cell types far exceeded the
number of DNA methylation changes. Nevertheless, alterations
in DNA methylation were enriched at genes with immune sys-
tem function. CGIs showed more dynamic methylation pat-
terns than elsewhere in the genome and, intriguingly, most CGI
methylation changes occurred at intragenic orphan CGIs.
There was a general inverse correlation between increased DNA
methylation and gene expression, yet differentially methylated
intragenic CGIs often lacked the active histone modification
H3K4me3, regardless of DNA methylation state. This suggests
that although these intragenic CGIs are likely to be sites of tran-
scriptional initiation in other lineages, they do not appear to act as
promoters in immune cells. Our findings suggest that CGI meth-
ylation plays a limited role in the terminal differentiation of im-
mune cells. However, the predominance of cell type–specific
methylation at intragenic CGIs raises the possibility that they
Figure 1. Cell type–specific methylation in the hematopoietic lineage detected by MAP-seq preferentially occurs at CGIs. (A) The immune cell
lineage with the cell types investigated shown in red. HSC: hematopoietic stem cell. (B) The number of CGI methylation, non-CGI-associated
methylation, and gene expression changes observed when CD4 T-cells were compared to Th2, Th1, B cells, dendritic cells (DC), and brain. (C,D) The
location of methylation differences detected by MAP-seq. The fraction of the genome that can be interrogated by MAP-seq was categorized as
overlapping a CGI (CGI), not overlapping but within 2 kb of a CGI (0–2 kb), or >2 kb from a CGI (>2 kb). The location of DNA methylation changes
was then determined and expressed as the number of methylation changes occurring per kilobase (kb) of genome in each category. (C ) Location of
all DNA methylation changes occurring between different immune cells. (D) Location of DNA methylation changes occurring between brain and
CD4 cells.
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CpG island methylation in hematopoietic cells
represent major regulatory sites of differential gene expression
during lineage specification.
Results
Methylation changes between immune cells are small
in number and show an association with
developmental relatedness
We used MBD affinity purification coupled to high-throughput
sequencing to assessDNAmethylation inB cells, dendritic cells, and
CD4 T-cells isolated from mouse spleen, as well as in vitro differ-
entiated Th1 and Th2 cells (Fig. 1A). MAP-seq interrogates sites with
a CpG density of 3.3 CpGs per 100 bp and above (Supplemental Fig.
S1) and therefore potentially detects 7.4 million CpG sites in the
genome. This includes all CGIs and many relatively CpG-rich
regions. MAP-seq gave ;17-fold coverage over these regions.
Comparison of DNA methylation patterns between different
immune cell types revealed surprisingly few differences both at
CGIs and non-CGI regions (Fig. 1B; Supplemental Table S2). In gen-
eral, the number of DNA methylation differences mirrored de-
velopmental distance, with just 16 CGIs showing differential
methylation between CD4 T-cells and Th1 cells, compared to 83
CGIs showing differential methylation between CD4 T-cells and
more distantly related B-cells. Nine CGIs showing differential
methylationwere confirmed by bisulfite genomic sequencing, and
all were consistent with theMAP-seq results (Supplemental Fig. S2;
Supplemental Table S3). However, bisulfite analysis of methylation
on individual DNA strands did not support the occurrence of allele-
specific DNAmethylation changes (Supplemental Fig. S2). We then
compared our immune cell methylation data to a more distantly
related tissue. For this, we used a previously determined MAP-seq
profile for mouse brain (Skene et al. 2010). The number of DNA
methylation differences between brain andCD4 cells was over 2000
at CGIs, about 100-fold higher than between CD4 cells and Th1
cells, and ;20,000 at non-CGI-associated regions (Fig. 1B). Inter-
estingly, brain showed a general loss of CGI methylation compared
to immune cells (datanot shown).Our findings suggest that the vast
majority of DNA methylation changes arise early in lineage com-
mitment, while only a few are acquired during the later stages of
terminal differentiation. A similar conclusion has been drawn by
analysis of promoter methylation during the differentiation of
embryonic stem cells to neurons (Mohn et al. 2008).
We then compared our DNA methylation data with gene
expression profiles in the equivalent cell populations using Illu-
mina BeadChip expression arrays. Gene expression differences of
twofold or more between immune cell types were numerous and,
in contrast to DNAmethylation changes, did not correlate closely
with developmental relatedness. For example, more genes were
differentially expressed between closely related CD4 cells and
Th1 cells (2811) than between more diverged CD4 and dendritic
cells (2059; x2-test, P < 2.2 3 1016) (Fig. 1A,B). Gene expression,
therefore, reflects functional adaptation of immune cells, rather
than their developmental relationship. Comparing CD4 cells
with brain revealed that the number of DNA methylation
changes (>22,000) is significantly higher than the number of gene
expression differences (5719). This is in contrast to comparisons
between different immune cell types, where gene expression dif-
ferences vastly outnumber DNA methylation changes. These
findings suggest that differential methylation, at least at the 7.4
million sites we are able to detect using MAP-seq, may not play
a major role in regulation of gene expression during terminal
differentiation.
Cell type–specific DNA methylation in the immune system
detected by MAP-seq occurs preferentially at CGIs
We analyzed where most of the cell type–specific methylation in
the immune system occurs and found that proportionally more
changes take place at CGIs than elsewhere in the genome. This is in
contrast to recent reports suggesting that tissue-specific methyla-
tion preferentially occurs at the edges of CGIs (Irizarry et al. 2009; Ji
et al. 2010). We categorized the fraction of the genome that can be
interrogated by MAP-seq as overlapping a CGI (CGI), not over-
lapping but within 2 kb of a CGI (0–2kb), or >2 kb from a CGI (>2
kb) and observed that the flanks of CGIs showed no preference for
cell type–specific methylation compared to the rest of the genome
at the 7.4 million CpG sites examined in our study. This was the
case when methylation differences between cells of the immune
system were examined (Fig. 1C) and also when CD4 T-cells were
compared to a distantly related tissue, brain (Fig. 1D). We used
a comprehensive, biologically defined mouse CGI set (Illingworth
et al. 2010) to examine the location of methylation changes be-
tween cell types. Using other bioinformatically defined CGI sets
for analysis did not result in enrichment for DNA methylation
changes at CGI shores (Supplemental Fig. S3). In addition, we
specifically examined the average number of MAP-seq hits in the
flanks of CGIs differentially methylated in dendritic cells com-
pared to Th1 cells and brain compared to CD4 cells. The greatest
differences in read number between the different cell types were
seen over the body of the CGI and not in the 2-kb flanking re-
gions (Supplemental Fig. S4).
CGI methylation differences preferentially occur within genes
that have immune system function
We asked whether the relatively small number of DNA methylation
changes at CGIs are preferentially associated with genes involved in
immune cell function. Analysis of gene ontology terms associated
with genes showing cell type–specific CGI methylation revealed an
enrichment for genes involved in immunity and defense, cytokine/
chemokine-mediated immunity, and developmental processes (see
Methods for gene ontology analysis) (Supplemental Table S4). These
ontology terms were the only ones over-represented. In contrast,
genes showingdifferentialCGImethylationbetweendistantly related
brain and CD4 cells were involved in a broader range of biological
processes, only some of which were associated with neuronal func-
tion (see Supplemental Table S4).
Genes that show differential methylation in immune system
cells were also examined individually with respect to function, and
many were found to have documented roles in the immune system
(Table 1). Significantly, the only methylation difference between
Th1 and Th2 cells occur in the Gata3 gene (Fig. 3F,G, see below),
which encodes the transcription factor determining Th2 cell fate
(Nawijn et al. 2001). The only gene-associated CGIs to show a DNA
methylation difference between CD4 cells and both Th1 and Th2
cells are located in Dtx1, a gene which suppresses T-cell activation
and is down-regulated when T-cells are activated (Liu and Lai 2005),
and Kcnn4 (Fig. 4A, see below), which codes for a calcium-activated
potassium channel involved in T-cell activation (Begenisich et al.
2004). We conclude that, despite their low number, DNA methyl-
ation changes colocalize with genes that play functionally impor-
tant roles in that cell type.
Deaton et al .
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Cell type–specific methylation preferentially occurs
at intragenic CGIs and this negatively correlates
with gene expression
CGIs are frequently associated with gene promoters, but we re-
cently identified large numbers of ‘‘orphan’’ CGIs that are not
associated with annotated TSSs (Illingworth et al. 2010). Orphan
CGIs account for approximately half of CGIs in both human and
mouse and consist of two subsets: intragenic and intergenic CGIs
(Fig. 2A,B). Strikingly, differential CGI methylation between all
immune cell types predominantly occurred at non-TSS-associ-
ated CGIs, specifically those located within transcription units
(Fig. 2C,D). Altogether, 2% of intragenic CGIs were involved in
DNA methylation transitions, compared to 0.28% of annotated
promoter CGIs (Fig. 2D). Thus, intragenic CGIs are distinct from
TSS-associated and intergenic CGIs with regard to cell type–specific
methylation. When brain and CD4 cells are compared, the ma-
jority of tissue-specific methylation also occurs at intragenic CGIs
(Supplemental Fig. S5).
Given the increased frequency of differential methylation
detected at intragenic CGIs, we examined the relationship between
gene expression and cell type–specific methylation for gene-asso-
ciated intragenic CGIs in immune cells. In most cases (74%), alter-
ations in CGI methylation were not associated with discernable
differences in expression of the associated gene. Focusing on the
26% of cases where DNA methylation and gene expression both
changed, we observed that increased intragenic CGI methylation
was most often linked to decreased expression of the gene in which
the CGI was located. Similarly, decreased methylation associated
with increased gene expression (70% of cases) (Fig. 3A,B). To in-
vestigate whether this negative correlation between cell type–spe-
cific intragenic CGI methylation and gene expression was a general
phenomenon and not an artefact of the small number of methyl-
ation differences detected between different immune system cells,
we compared CD4 cells to distantly related brain, which shows
hypomethylation of CGIs compared to immune cells. In brain,
decreased DNA methylation at intragenic CGIs tended to associate
with increased gene expression (82% of cases) (Fig. 3C,D). This
supports the negative correlation between cell type–specific in-
tragenicCGImethylation andexpressionof the associatedgene that
was observed between immune cell types.
A key immune cell regulator showing a negative correlation
between intragenic CGI methylation and expression is the Gata3
gene, which is expressed specifically in Th2-cells (Fig. 3E) and de-
termines Th2 cell identity (Nawijn et al. 2001). The only methyl-
ation difference between Th1 and Th2-cells occurred at an in-
tragenic CGI in the Gata3 gene (Fig. 3F) and was confirmed by
bisulfite sequencing and found to be relatively subtle (54% in Th1
compared to 72% methylation in Th2-cells) when in vitro differ-
entiated Th1 and Th2-cells were compared (Fig. 3G). However, IL4-
producing Th2 cells isolated from a Th2-inducing infection with
Schistosoma mansoni showed complete demethylation of this CGI
after an 8-wk infection (8%methylation) (Fig. 3G). This confirmed
that DNAmethylation changes identified at intragenic CGIs using
in vitro T-cell differentiation are relevant in vivo. Complete
demethylation of the Gata3 CGI, as seen in vivo, may require
a longer time period than is possible in vitro.
Intragenic CGI methylation at Kcnn4 and Gata3 shows an inverse
relationship with H3K4me3
Unmethylated CGIs are frequently associated with the transcrip-
tionally permissive histone modification H3K4me3, regardless of
gene activity (Guenther et al. 2007;Mikkelsen et al. 2007; Illingworth
Table 1. Cell type–specific CGI methylation affects genes with immune system function
Gene
Cell types showing a change
in CGI methylation
(hypomethylated cell type
in brackets) Function References
Gata3 Th1 (vs. Th2) Th2-specific transcription
factor
(Nawijn et al. 2001)
Dtx1 Th1, Th2 (vs. CD4/DC) Suppression of T-cell
activation
(Liu and Lai 2005)
Kcnn4 CD4, DC, B cell (vs. Th1/Th2) Potassium channel involved
in T-cell activation
(Begenisich et al. 2004)
Fgr CD4 (vs. DC) Regulation of myeloid cell
chemokine signaling
(Zhang et al. 2005)
Sema4a CD4, Th1, Th2 (vs. DC) Co-stimulation, T-cell
differentiation
(Kumanogoh et al. 2005)
Bcl11b Th1 (vs. DC) Thymocyte development (Wakabayashi et al. 2003)
Runx3 B cell (vs. CD4) Transcription factor,
promotes Th1 cell fate
(Djuretic et al. 2007)
Klf2 DC (vs. Th1) Transcription factor
regulating IL-2 production
early in T-cell activation
(Wu and Lingrel 2005)
Il10ra CD4 (vs. B cell) Interleukin-10 receptor,
regulation of immune
response.
(Pils et al. 2010)
Tnfaip2 DC (vs. Th1/Th2) Pro-inflammatory gene (Mookherjee et al. 2006)
Cxcr5 CD4 (vs. B cell) Chemokine receptor (Hardtke et al. 2005; Junt et al. 2005)
Notch 2 Th1,Th2,CD4 (vs. DC) Signaling during immune
cell differentiation
(Cheng et al. 2003; Fiorini et al. 2009)
Il16 Th1 (vs. DC) T-cell chemoattractant,
regulation of T-cell growth.
(Cruikshank and Little 2008)
A selection of the immune system genes that display differential CGI methylation is shown along with the relevant references, although this list is not
exhaustive. For each example, the cell type(s) showing a decrease in methylation (hypomethylation) is indicated in parentheses.
CpG island methylation in hematopoietic cells
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et al. 2010; Thomson et al. 2010). This is true for both TSS and in-
tragenic CGIs, although the proportion of intragenic CGIs marked
by H3K4me3 is smaller, with 41% of intragenic CGIs positive for
H3K4me3 in embryonic stem (ES) cells compared to 96% of TSS
CGIs (Illingworth et al. 2010).MethylatedCGIs, on the other hand,
do not associate with H3K4me3, reflecting transcriptional silenc-
ing at these sites (Meissner et al. 2008; Illingworth et al. 2010;
Maunakea et al. 2010). Recent studies have suggested a mechanistic
explanation for this phenomenon whereby the protein CFP1 binds
to unmethylated CGIs and facilitates recruitment of the SET1H3K4
methyltransferase complex (Thomson et al. 2010). We reasoned
that cell type–specific DNA methylation at intragenic CGIs should
lead to a decrease in H3K4me3 at these sites. This was, indeed, the
case at a CGIwithin the body of theKcnn4 gene,which ismarked by
H3K4me3 inTh1 cells,where it is hypomethylated, but not inB cells
or dendritic cells, where it is heavily methylated (Fig. 4A,B).
Because of its pivotal role in Th2 cell differentiation
(Nawijn et al. 2001), the Gata3 gene is of particular interest and,
furthermore, shows the only methylation difference we ob-
served between Th1 and Th2 cells. At the Gata3 intragenic CGI
(Fig. 4C), a small decrease in DNA methylation in Th2 cells (Fig.
3G) was accompanied by a large increase in H3K4me3 (Fig. 4D).
On the other hand, H3K4me3 levels at the unmethylated TSS
CGI did not vary between Th1 and Th2 cells (Fig. 4C,D) raising
the possibility that the intragenic CGI has a regulatory role at
this locus.
Silent chromatin configurations at differentially methylated
intragenic CGIs
We next asked whether an association between decreased DNA
methylation and increased H3K4me3 at intragenic CGIs, such as
that observed at Kcnn4 and Gata3, was a common feature of cell
type–specific methylation. We examined H3K4me3 distribution
genome-wide in Th1 and dendritic cells,
as these cell types showed the greatest
number of differences in CGI methyla-
tion. Of 63 intragenic CGIs showing dif-
ferential methylation between Th1 and
dendritic cells, 55% lacked H3K4me3 in
both cell types (Fig. 5A). Of the remaining
45%, almost half showed differential
H3K4me3 similar to that detected at
Kcnn4 and Gata3. In the remainder of
cases, changes in DNA methylation oc-
curred at CGIs positive for H3K4me3 in
both immune cell types, or differential
H3K4me3 was undetectable using our
parameters (Fig. 5A).
The absence of the H3K4me3 mark
at most differentially methylated in-
tragenic CGIs suggests that they are as-
sociated with a transcriptionally inert
chromatin environment, regardless of
the DNA methylation state. It follows
that a DNA methylation-independent
mechanism may explain the absence of
this ‘‘active’’ chromatin modification.
Polycomb-mediated silencing, marked
by the presence of H3K27me3, is a po-
tential alternative as 58% of CGIs lack-
ing H3K4me3 in mouse brain have this
chromatin mark (Thomson et al. 2010). These histone modifi-
cations can also occur together in the context of biva-
lent chromatin (Bernstein et al. 2006; Mikkelsen et al. 2007).
H3K27me3 enrichment at differentially methylated CGIs lo-
cated in the gene bodies of Tead3 and Kctd17 was tested using
ChIP-qPCR in Th1 and dendritic cells. Levels were compared to
those at the Sox2 promoter, which has been reported to be si-
lenced by H3K27me3 (Mikkelsen et al. 2007), and the CGI pro-
moter of the housekeeping gene Actb (Fig. 5B). We found that
the Tead3 and Kctd17 intragenic CGIs were marked by H3K27me
in both Th1 and dendritic cells, although levels varied between
the two genes (Fig. 5B). This suggests that silencing by poly-
comb, as well as, or as an alternative to, DNA methylation may
explain the lack of H3K4me3 and hence the transcriptionally
inert state at many cell type–specifically methylated intragenic
CGIs.
To understand the relationship between H3K4me3 and
H3K27me3 at differentially methylated intragenic CGIs, we per-
formed H3K27me3 ChIP-seq in Th1 and dendritic cells. We found
that half of the differentially methylated intragenic CGIs negative
for H3K4me3 were marked by H3K27me3, indicating that poly-
comb silencing contributes to a transcriptionally inert state at
many of these CGIs but does not account for all sites devoid of this
active chromatin modification. H3K27me3 levels at Tead3, Kctd17
(Fig. 5C,D), Sox2, and Actb (Supplemental Fig. S6A,B) were con-
sistent with ChIP-qPCR results. Examples of other differentially
methylated CGIs which lack H3K4me3 but are marked by
H3K27me3 (located at the Tnfaip2 and 2810459M11Rik loci) are
shown in Supplemental Figure S6C,D. However, H3K27me3 itself
is not refractory to H3K4me3, as evidenced by the existence of
a small number of differentially methylated bivalent intragenic
CGIs, marked by H3K4me3 and H3K27me3 in both Th1 and
dendritic cells (Supplemental Fig. S7). Altogether, our findings
highlight that CGIs showing cell type–specific differences in DNA
Figure 2. Cell type–specific methylation occurs at intragenic CGIs. (A) CGIs can be transcription start
site (TSS)-associated, intragenic, or intergenic. (B) The distribution of CGIs in the mouse genome
(Illingworth et al. 2010). (C ) Pairwise comparisons of immune cell types [dendritic cells (DC), Th1 cells,
Th2 cells, B cells, and CD4 T-cells] showing the location of methylation changes in each comparison. (D)
The percentage of CGIs in each class showing a DNA methylation change in any of the immune cell
comparisons. Each CGI was only counted once even if it changed in multiple comparisons.
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Figure 3. Differential intragenic CGI methylation negatively correlates with gene expression. Genes showing both a change in DNA methylation at an
intragenic CGI and a change in gene expression were plotted. (A) All immune cell comparisonswhere (+) denotes an increase and (-) denotes a decrease in
expression or methylation. (B) The percentage of methylation changes showing a positive or negative correlation with gene expression in immune cells.
(C ) Brain compared with CD4 cells. (+) denotes an increase and (-) a decrease in expression or methylation. (D) The percentage of methylation changes
between brain and CD4 cells showing a positive or negative correlation with gene expression. (E) Expression of Gata3 (relative to Eef1A1) in Th1 and Th2
cells verified by qRT-PCR. (F) MAP-seq read density profile (red) showing differential methylation at an intragenic CGI (asterisk) in theGata3 gene. CGIs are
shown in blue. The arrow indicates the origin and direction of transcription. (G) Confirmation of Gata3 methylation by bisulfite sequencing of in vitro
differentiated Th1 and Th2 cells as well as Th2 cells isolated from a Schistosoma mansoni infection. The gray bar on the MAP-seq profile (panel F ) indicates
the region interrogated. (Filled circles) Methylated CpGs. (Empty circles) Unmethylated CpGs.
CpG island methylation in hematopoietic cells
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Figure 4. Decreased DNAmethylation is associated with increased H3K4me3 at the Kcnn4 and Gata3 intragenic CGIs. (A) MAP-seq read density profile
(red) showing amethylation difference between Th1 cells, dendritic cells (DC), and B cells at a CGI in Kcnn4 gene (asterisk). (B) ChIP combined with qPCR
across the Kcnn4 locus reveals specific enrichment for H3K4me3 in Th1 cells where the intragenic CGI is hypomethylated. (C ) The methylation difference
between Th1 and Th2 cells at the Gata3 locus (asterisk) is associated with a difference in H3K4me3 specifically over the intragenic CGI (red box) (D). For
both genes, the arrow indicates the origin and direction of transcription, blue indicates CGIs, and black lines indicate the position of PCR primer pairs.
Deaton et al .
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methylation are often transcriptionally inert regardless of meth-
ylation state. They also demonstrate the existence of multiple
modes of regulation for intragenic CGIs and highlight the com-
plexity of silencing mechanisms at these regions.
Intragenic CGIs showing cell type–specific methylation
in the immune system may be promoters
in other tissues
Many intragenic CGIs act as promoters for alternative transcripts
of unknown functional significance (Illingworth et al. 2010;
Maunakea et al. 2010). More than half are associated with one or
more signs of promoter activity, including H3K4me3, RNAPII, and
the presence of a capped transcript (Illingworth et al. 2010;
Maunakea et al. 2010). It is likely that this proportion will increase
as further tissues are examined. Methylated intragenic CGIs, on
the other hand, lack both H3K4me3 and RNAPII (Illingworth et al.
2010; Maunakea et al. 2010). Surprisingly, we found that the ma-
jority of intragenic CGIs showing cell type–specific methylation
in the immune system lack H3K4me3 even when hypometh-
ylated. Comparison between immune cells and brain, however,
indicates that this reflects tissue-specific marking of intragenic
CGIs by H3K4me3. In brain, 13% of intragenic CGIs that were
negative for H3K4me3 in dendritic cells were positive for
H3K4me3. Conversely, 11.5% of intragenic CGIs that lacked
H3K4me3 in brain were H3K4me3-positive in dendritic cells (all
intragenic CGIs were examined) (Fig. 6A). A similar trend was
observed when dendritic cells were compared to ES cells (Supple-
mental Fig. S8). Our findings emphasize the highly variable ac-
tivity of intragenic CGI promoters between tissues. This contrasts
Figure 5. Most differentially methylated intragenic CGIs are depleted
for H3K4me3 in immune cells. (A) Association of intragenic CGIs differ-
entially methylated in Th1 and dendritic cells with H3K4me3 as assessed
by ChIP-seq. (Yellow) CGIs where increased DNA methylation is associ-
ated with decreased H3K4me3 (n = 11). (Green) CGIs that are positive for
H3K4me3 in both cell types despite a difference in methylation (n = 10).
(Red) CGIs that lack H3K4me3 in both cell types (n = 35). (Blue) CGIs
showing a nonsignificant change in H3K4me3 (n = 5) or where increased
DNA methylation is associated with increased H3K4me3 (n = 2). (B) ChIP-
PCR reveals enrichment for H3K27me3 at Tead3 and Kctd17 in Th1 and
dendritic cells (DC) as well as at Sox2 (positive control). The active Actb
gene acted as a negative control. These results were confirmed and ex-
tended using H3K27me3 ChIP-seq. MAP-seq (red), H3K27me3 ChIP-seq
(cyan), and H3K4me3 (green) read density profiles for intragenic CGIs in
the (C ) Tead3 and (D) Kctd17 genes that lack H3K4me3 in Th1 and
dendritic cells, despite showing differential methylation between the two
cell types (asterisked CGI).
Figure 6. Intragenic CGIs frequently show tissue-specific H3K4me3,
and differentially methylated intragenic CGIs have evidence for promoter
function. (A) The percentage of TSS and intragenic CGIs that are positive
for H3K4me3 in brain (gray), dendritic cells (black), or both (stripes). (B)
RNAPII binding data for ES cells and CAGE data for mouse tissues was used
to infer whether intragenic CGIs have evidence for association with a TSS
(see Methods). H3K4me3 positive and H3K4me3 negative differentially
methylated intragenic CGIs are shown, along with all intragenic CGIs in
the mouse genome.
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with the situation for annotated TSS CGIs, the vast majority of
which possess H3K4me3 in both dendritic cells and brain (Fig. 6A).
To test intragenic CGIs differentially methylated in the im-
mune system more directly for promoter activity in other cell
types, we looked for direct evidence of transcriptional initiation at
these sites by examining RNAPII binding in ES cells (Illingworth
et al. 2010) and cap analysis of gene expression (CAGE) data from
a panel of mouse tissues that did not include the immune cells
investigated here (Faulkner et al. 2009). Approximately 40%–50%
of these CGIs show evidence for transcriptional initiation by at
least one of these criteria, and this is comparable to the proportion
of all intragenic CGIs that are associated with TSS evidence (Fig.
6B). These findings suggest that, although the majority of differ-
entiallymethylated intragenic CGIs are associatedwith a repressed
chromatin state in the immune system, they may represent active
promoters in other cell types. One possibility is that they function
during the early stages of commitment to the hematopoietic line-
age when the DNA methylation pattern is set.
Discussion
Cell type–specific methylation is rare between cells
from the same lineage
We examined DNA methylation in terminally differentiated cells
from the hematopoietic lineage and found only a small number of
differences between cells both at CGIs and at the non-CGI-associated
regions amenable to interrogation byMAP-seq. Induction of Th1 and
Th2 cells from CD4 T-cells was accompanied by only a handful of
detectable changes genome wide. In contrast to the relative homo-
geneity of DNA methylomes in this lineage, we observed very dif-
ferentDNAmethylationpatternswhen immune cellswere compared
with brain. This confirms that major changes in DNA methylation
status are detectable using this methodology. Furthermore, it sug-
gests that large changes in DNA methylation patterns may occur
early in lineage commitment, with far fewer alterations accompa-
nying terminal differentiation. A similar conclusion was drawn for
annotated promoters in an in vitro differentiation model of gluta-
matergic pyramidal neurons (Mohn et al. 2008). Dynamic alter-
ations in DNA methylation appeared to occur prior to the multi-
potent progenitor state, leaving relatively few additional changes in
the later stages of differentiation. Our data extends this conclusion
to a major fraction of the genome in a different cell lineage.
In contrast to the relative stability of DNA methylome, gene
expression programs showed large numbers of greater than two-
fold changes between different cells of the hematopoietic lineage.
The discrepancy between large scale transcriptional variations
arising during terminal differentiation and far fewer alterations in
the DNA methylome leads us to infer that DNA methylation dy-
namics do not play a major role in determining cell type–specific
gene expression programs during late differentiation. A caveat to
this conclusion is that MAP-seq does not sample the entire DNA
methylome. We estimate that the conditions used for MAP-seq
recover DNA with a methyl-CpG density of 3.3 CpGs per 100 bp
or above, which potentially includes 6.5% of the mouse genome
(excluding repeats). Thismeans that over one-third (7.4million) of
the 21.3 million CpG sites are potentially detectable if densely
methylated. The detectable fraction includes all CGIs in the ge-
nome. While it remains possible that critical DNA methylation
changes in undetected regions of the genome are involved in
choreographing gene expression, our data rule out the possibility
that modulation of CGI methylation plays a large role in this.
CpG islands are more dynamically methylated
than their flanking DNA sequences
Several studies have reported that the regions flanking CGIs (so-
called ‘‘CpG island shores’’) are much more likely to be dif-
ferentially methylated than CGIs themselves (Doi et al. 2009;
Irizarry et al. 2009). This conclusion was recently extended to
the hematopoietic lineage (Ji et al. 2010). The methodology relies
on cleavage with a DNA methylation-specific type I restriction
enzyme, followed by hybridization to microarrays carrying rela-
tively GC-rich regions of the genome. Using a distinct technology
(MAP-seq) that also preferentially sees CpG-rich sequences, we did
not detect more variable DNA methylation in CGI shores. In fact,
between immune system cells, we observed fewer changes in CGI
flanks than in CGIs themselves. Moreover, CGI flanks were not
more variable in the cells we studied than other detectable regions
in the genome at large. A resolution of this discrepancy awaits
the widespread application of whole methylome sequencing ap-
proaches (Lister et al. 2009).
Intragenic CGIs most frequently show cell
type–specific methylation
We recently described a comprehensive annotation of CGIs in
human and mouse, identifying three classes: TSS, intragenic,
and intergenic CGIs (Illingworth et al. 2010). The latter two
classes were grouped as ‘‘orphan CGIs’’ to reflect our ignorance
about their functional significance. This study represents the
first analysis of cell type–specific methylation using this com-
prehensive CGI set. Our results show that CGIs located within
gene bodies are far more likely to show cell type–specific
methylation in the immune system than other CGIs. This dem-
onstrates that intragenic CGIs are distinct from TSS and intergenic
CGIs, even though other features such as DNA sequence char-
acteristics, frequent presence of H3K4me3, and RNAPII are
shared with the other classes. Our results suggest that intragenic
CGIs may share a distinct biological role. Most previous stud-
ies examining tissue-specific CGI methylation have focused on
annotated promoters (Weber et al. 2007; Meissner et al. 2008;
Mohn et al. 2008) and agree with our findings demonstrating
that TSS CGIs rarely show differential methylation. It is likely
that a fuller understanding of intragenic CGIs will be important
for elucidating the extent and significance of cell type–specific
methylation.
Differentially methylated intragenic CGIs tend to be silent
in immune cells regardless of DNA methylation state
Intragenic CGIs are frequently associated with H3K4me3 when
they are unmethylated (Illingworth et al. 2010; Maunakea et al.
2010).We investigatedwhether cell type–specific CGImethylation
was associated with a specific loss of H3K4me3 in the methylated
cell type. Although this was the case for someCGIs (e.g.,Kcnn4 and
Gata3), when all intragenic CGIs differentially methylated in Th1
and dendritic cells were examined, the majority lacked H3K4me3,
even in the cell type where they were unmethylated. This suggests
that these CGIs are associated with a repressive chromatin envi-
ronment regardless of methylation state. Previous studies have
found that CGIs negative for H3K4me3 in brain are often marked
byH3K27me3 (Thomson et al. 2010), and this was the case for half
of the differentially methylated intragenic CGIs lacking H3K4me3
in Th1 cells and dendritic cells.
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Differentially methylated intragenic CGIs may represent
novel promoters
There is evidence for transcriptional initiation at many non-TSS-
associated CGIs (Illingworth et al. 2010; Maunakea et al. 2010).
Accordingly it has been suggested that CGIs within gene bodies act
as alternative promoters for the associated gene and that cell type–
specific methylation at these sites reflects silencing of these pro-
moters (Illingworth et al. 2010; Maunakea et al. 2010). This has
been shown to be the case for intragenic CGIs in the Shank3 and
Nfix genes (Maunakea et al. 2010). However, we found that the
majority of intragenic CGIs showing cell type–specific methyla-
tion were deficient in H3K4me3 in immune cells even when
unmethylated. This implies that these CGIs are not active pro-
moters in immune cells and conflicts with the idea that differential
methylation reflects silencing of alternative promoters. Differen-
tial DNAmethylation in the immune systemmay reflect stochastic
acquisition of methylation at already silent loci or cell type–de-
pendent differences in the use of DNA methylation as a silencing
mechanism. There is, however, evidence that these differentially
methylated intragenic CGIs may represent promoters active in
other cell types. As intragenic CGIs are distinct from other CGIs in
terms of their more frequent cell type–specific methylation, one
possibility is that they act as promoters for transcripts with par-
ticularly restricted expression patterns and/or noncoding tran-
scripts. This may explain why they have escaped annotation by
conventional means.
Intragenic CGI methylation may affect gene expression
by an indirect mechanism
We observed that increased intragenic CGI methylation, when
associated with a gene expression change, negatively correlates
with gene expression. The functional significance of this correla-
tion is unclear, as these CGIs are often far from the gene’s anno-
tated promoter and do not appear to have novel promoter activity
in immune cells. One possibility is that intragenicCGImethylation
may impede gene expression by affecting transcriptional elonga-
tion. For example, transcriptional elongation through densely
methylated CpGs has been reported to be less efficient than
through unmethylatedCpG-rich sequences (Lorincz et al. 2004). It
is evident, however, that intragenic methylation is not refractory
to transcription because the AirnCGI is present within the body of
the expressed Igf2r gene (Sleutels et al. 2002), and gene body
methylation at lower density is characteristic of actively tran-
scribed genes (Ball et al. 2009; Deng et al. 2009; Rauch et al. 2009).
Accordingly, we observedmethylated intragenic CGIs in a number
of actively transcribed genes in immune cells. Despite these pre-
cedents, it cannot be ruled out that dense intragenic methylation
can modulate transcription in certain instances.
Another way in which intragenic CGI methylation might
affect gene expression is through regulation of noncoding tran-
scripts that affect transcription of the associated gene. Intriguingly,
there is evidence that long intergenic noncoding RNAs (ncRNAs)
can positively regulate the expression of nearby genes (Orom et al.
2010). It is possible that ncRNAs originating from some intragenic
CGIs may also play such a role. Silencing of the regulatory ncRNA
promoter by DNA methylation might explain the negative corre-
lation between CGImethylation and gene expression observed for
some differentially methylated intragenic CGIs.
A third possible function of intragenic CGI methylation is in
modulating alternative splicing. It has been proposed that a closed
chromatin environment over an alternatively spliced exon might
slow down the passage of RNAPII and give the splicing machinery
more time to recognize that exon, thus facilitating its inclusion in
the transcript (Kornblihtt 2006). There is evidence that siRNA-
mediated histonemodifications (Allo et al. 2009) and the SWI/SNF
nucleosome remodelling complex (Batsche et al. 2006) affect
splicing in such a manner. It is, therefore, conceivable that differ-
ences in intragenic CGI methylation might alter transcript pro-
cessing in specific cell types. Further studies are now required to
decipher how intragenic CGIs can modulate the expression of
their associated genes as well as the mechanisms allowing their
precise regulation during cell lineage commitment.
Methods
Immune cell isolation
Cells were isolated from the spleens of C57/BL6 mice, and bi-
ological samples consisted of pools of individual mice aged 6–12
wk (see Supplemental Table S1 for sample details). Red blood cells
were lysed using red blood cell lysing buffer (Sigma) according to
the manufacturer’s instructions. To isolate conventional myeloid
dendritic cells, plasmacytoid dendritic cells (which are lymphoid
in origin) were first depleted using PDCA microbeads (Miltenyi
Biotec), and then CD11c+ dendritic cells were positively selected
using CD11c microbeads (Miltenyi Biotec), both used according
to the manufacturer’s instructions; cell purity was typically 73%–
90%. CD4 T-cells were purified in a similar manner using CD4
microbeads (Miltenyi Biotec), giving purities of 87%–97%. For
gene expression analysis, naive CD4 cells (CD44 low, CD62L high)
were sorted using a BD FACS Aria machine with purity >90%. B
cells (CD19+) were sorted in a similar manner with purity >90%.
Immune cell culture
To generate differentiated Th1 and Th2 cell populations, cells
isolated from the spleen were stimulated with plate-bound a-CD3
and a-CD28 (1.6 mg; BD Pharmingen), and recombinant murine
IL-2 (20ng/mL; Peprotech) was added. For Th1 differentiation, IL-
12 (5ng/mL; R&D Systems) and anti-IL4 (5mg/mL; BD Pharmin-
gen) were added. For Th2 polarization, IL4 (10ng/mL; Peprotech)
and anti-IL-12 (5mg/mL; BioLegend) were added. To assess cyto-
kine production by intracellular staining, PMA (50ng/mL), ion-
omycin (500ng/mL), and Golgistop (1:2000; BD Pharmingen)
were added to cultures on day 7. After 4 h, cells were harvested,
permeablized, and stained with antibodies against IFNG (Bio-
legend) or IL4 (BD Pharmingen), to confirm Th1 and Th2 cell
identity, respectively. For DNA methylation analysis, cells were
sorted based on IFNG production (Th1 cells) or IL4 production
(Th2 cells).
Th2 cells were also isolated from mice infected with Schisto-
soma mansoni. At 8 wk post-infection, spleens were harvested, and
CD4 cells were purified with CD4 microbeads (Miltenyi Biotec)
and then stimulated with PMA (10ng/mL), ionomycin (1mg/mL),
and Golgistop (1:1000) for 5 h. Cells were permeabilized and
stained with IL4 and IFNG antibodies. The IL4+ cell population
was sorted as above.
DNA extraction and preparation for MAP
Cells were incubated in buffer containing 10mM Tris-HCl pH 8,
400mM NaCl, 3mM EDTA pH 8, 1% SDS supplemented with pro-
teinase K (40mg/mL) at 55°C overnight. DNA was then extracted
using phenol:chloroform:isoamylalcohol, followed by isopropanol
precipitation. DNA was fragmented to an average size of 500 bp
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using a Diagenode Bioruptor, and Illumina sequencing adaptors
were added prior toMAP as previously described (Skene et al. 2010).
For each cell type, two biological replicates were prepared.
MAP chromatography
MAP was performed using two sequential rounds of chromatog-
raphy as previously described (Skene et al. 2010) and tested by
performing PCR for known methylated regions.
Bisulfite sequencing
DNA was sonicated for 10 s using a Diagenode Bioruptor prior to
bisulfite treatment. Bisulfite treatment and sequencing were per-
formed as previously described (Illingworth et al. 2008).
RNA extraction and reverse transcription
RNA was extracted using TRI Reagent (Sigma) according to the
manufacturer’s instructions and DNase-treated using DNA-free
(Ambion). Reverse transcription was carried out using M-MLV re-
verse transcriptase (Promega) and random hexamer primers
(Roche).
Quantitative PCR
Quantitative PCR was carried out using SYBR Green SensiMix
(Quantace) according to the manufacturer’s instructions on a
LightCycler 480 (Roche). Primer sequences are available upon re-
quest.
Illumina BeadChip arrays
RNAwas labeledusing theTotalPrepRNAAmplificationkit (Ambion)
and hybridized to Illumina MouseWG-6 BeadChip arrays according
to themanufacturer’s instructions. Three biological replicates were
carried out for each cell type. Bead level data were summarized
using Illumina GenomeStudio, and data were normalized using
the average normalization method in GenomeStudio. Subsequent
analysis was carried out using GeneSpring GX10 (Agilent Tech-
nologies). In order to identify changes in gene expression between
cell types, genes with low expression (Flags absent) across all cell
types were removed, and statistical analysis was carried out to find
genes that were differentially expressed between any of the cell
types (one-way ANOVA, P # 0.5). Pairwise comparisons were per-
formed on this gene set, and genes changing at least twofold were
deemed to be differentially expressed. Brain gene expression stud-
ies were carried out on whole male brain from wild-type 5-wk-old
C57/BL6 mice, and analysis was performed as for immune cells.
Sample information is given in Supplemental Table S1.
Chromatin immunoprecipitation (ChIP)
ChIP was performed on Th1, Th2, and dendritic cells as previously
described (Schmiedeberg et al. 2009). For each immunoprecipita-
tion, cross-linked chromatin from ;4 million cells was incubated
with either 5 mg anti-H3K4me3 (07-473; Millipore) or 5 mg anti-
H3K27me3 (07-499; Millipore). Immunoprecipitated DNA was
then analyzed using quantitative PCR or high-throughput se-
quencing. Prior to sequencing, Illumina adaptors were ligated to
ChIP DNA samples as previously described (Skene et al. 2010).
Library preparation and Illumina sequencing
To produce Illumina libraries for sequencing, DNA to which Illu-
mina adaptors had been attached was amplified by 10–12 cycles of
PCR with primers complementary to the adaptor sequences, using
Phusion polymerase (Finnzymes), and the DNAwas purified using
QIAquick PCR Purification columns (Qiagen). The purified DNA
was attached to an Illumina flow cell for cluster generation. Libraries
were sequenced on the Illumina Genome Analyzer following the
standard protocol to generate single-end 37-bp reads. Reads were
mapped to the mouse genome (mm9–NCBIm37; repeat-masked)
using MAQ (Li et al. 2008) (http://maq.sourceforge.net/), and reads
with amapping score of$30were retained. One lane of sequencing
was carried out for each sample, and replicate samples were com-
bined to give two lanes of sequencing for each cell type. Detailed
sample information is given in Supplemental Table S1.
Analysis of high-throughput sequencing data
Mappedhigh-throughput sequencing data in the formofWIG files
were analyzed as described previously (Illingworth et al. 2010)
using a set of tools interfaced with an in-house version of the
Galaxy application (Taylor et al. 2007). Briefly, raw sequencing
data were normalized to the average read number across all sam-
ples of a given purification type in order to account for variable
sequence depth between samples. Peak-finding was then carried
out to identify regions of prominent enrichment using the fol-
lowing parameters: read height (H), length in bp (L), and gap
permitted in the length parameter (G). These were adjusted for
each purification type so that regions of known methylation or
histone modification status were isolated. The X and Y chromo-
somes were excluded from analyses in order to avoid spurious
results due to fluctuations in the proportion of male and female
DNA in samples. All analysis parameters are outlined in Supple-
mental Table S1.
Peak saturation analysis was carried out using representative
samples from each purification type (i.e., MAP-seq, H3K4me3
ChIP-seq, and H3K27me3 ChIP-seq). See Supplemental Methods
and Supplemental Figure S9 for further details.
To identify regions showing differential enrichment for
a particular modification (i.e., DNA methylation or H3K4me3),
peaks for each sample were combined to give a set of regions of
interest over which a sliding window analysis was performed. For
each region, the average number of hits per base was calculated in
100-bp windows with a 20-bp slide. Values were then compared
between samples giving a ratio for each window. If both windows
being compared contained less than four reads, this ratio was set to
one in order to remove spurious hits attributed to small fluctua-
tions at low read depth. Differentially enriched regions were
identified as those containing nine out of 13 contiguous windows
with a log2 ratio $1.8 (MAP-seq) or a log2 ratio $2 (H3K4me3
ChIP-seq). These parameters were selected so that known differ-
entially modified regions were identified (e.g., X-linked CGIs
which are differentially methylated between males and females).
Details of all differentially methylated CGIs identified are given in
Supplemental Table S2.
Differentiallymodified regionswere examined for association
with CGIs, RefSeq genes, TSSs, and other genomic features using
standard tools available on Galaxy. An association was defined
as direct overlap with a particular feature by at least 1 bp. The
CGIs examined were from the mouse CGI set characterized by
Illingworth et al. (2010), and RefSeq-annotated genes were used as
the gene set. CGIs were categorized as follows: TSS (overlap with
the annotated start site of any RefSeq gene), intragenic (not over-
lapping the TSS but located anywhere in the transcription unit),
and intergenic (no gene overlap). Brain methylation data was
obtained fromMAP-seq on cerebellum (Skene et al. 2010) and was
analyzed in parallel with the other MAP-seq samples. Brain
H3K4me3 data was from Thomson et al. (2010), ES cell RNAPII
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ChIP-seq data was from Illingworth et al. (2010), and CAGE data
was froma study by Faulkner et al. (2009). RNAPII peaks, as defined
by Illingworth and colleagues, or regions with more than five
CAGE tags, were taken as evidence of a TSS.
Analysis of gene ontology terms was carried out using the
PANTHER database (http://www.pantherdb.org; Thomas et al.
2003). A versionof the binomial test (Cho andCampbell 2000)was
used to identify overrepresented ontology terms with P # 0.05,
indicating significant enrichment. All CGI-associated genes were
used as a reference.
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